Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05877599 · ClinicalTrials.gov registry record · Phase 1

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
46
Enrollment target
18
Study locations

NCT05877599 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 46 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 18 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05877599, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
46 participants
Enrollment target
18
Study locations

Study Summary

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.

Conditions Studied

Breast Cancer Non-Small Cell Lung Cancer Ovarian Cancer Head and Neck Squamous Cell Carcinoma Pancreatic Adenocarcinoma Colorectal Carcinoma Other Solid Tumors

Interventions

  • BIOLOGICAL Autologous, engineered T Cells targeting TP53 R175H

Study Locations (18)

California

  • Research Site - Duarte
  • Research Site - Newport Beach
  • Research Site - Santa Monica

Florida

  • Research Site - Jacksonville
  • Research Site - Miami
  • Research Site - Tampa

North Carolina

  • Research Site - Charlotte
  • Research Site - Winston-Salem

Texas

  • Research Site - Houston
  • Research Site - Round Rock

Arizona

  • Research Site - Gilbert

Massachusetts

  • Research Site - Boston

New Jersey

  • Research Site - New Brunswick

New York

  • Research Site - New York

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2023-07-12
Est. Completion 2029-07-31
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05877599

The ClinicalTrials.gov registry entry for NCT05877599 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Autologous, engineered T Cells targeting TP53 R175H is the first listed.

NCT05877599 reports 18 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, North Carolina.

Frequently Asked Questions

What is clinical trial NCT05877599 about?

NCT05877599 is a clinical study titled "A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation". Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.

What is the current status of trial NCT05877599?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2023-07-12. Estimated completion is 2029-07-31.

What conditions does trial NCT05877599 study?

This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Pancreatic Adenocarcinoma.

What interventions are being tested in trial NCT05877599?

The interventions under investigation include: Autologous, engineered T Cells targeting TP53 R175H (BIOLOGICAL).

Who is sponsoring clinical trial NCT05877599?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05877599 being conducted?

This trial has 18 study locations across Arizona, California, Florida, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Non-Small Cell Lung Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.